Komjathy Andrew 4
4 · CATABASIS PHARMACEUTICALS INC · Filed Sep 19, 2019
Insider Transaction Report
Form 4
Komjathy Andrew
Chief Commercial Officer
Transactions
- Award
Stock Option (right to buy)
2019-09-18+44,500→ 44,500 totalExercise: $5.92Exp: 2029-09-17→ Common Stock (44,500 underlying)
Footnotes (1)
- [F1]This option was granted on September 18, 2019 and is subject to vesting over a four year period, with 25% of the shares vesting on the first anniversary of September 18, 2019 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.